These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 31227742

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
    Ratziu V, Sanyal AJ, Loomba R, Rinella M, Harrison S, Anstee QM, Goodman Z, Bedossa P, MacConell L, Shringarpure R, Shah A, Younossi Z.
    Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
    [Abstract] [Full Text] [Related]

  • 23. Gene expression profiling in human precision cut liver slices in response to the FXR agonist obeticholic acid.
    Ijssennagger N, Janssen AWF, Milona A, Ramos Pittol JM, Hollman DAA, Mokry M, Betzel B, Berends FJ, Janssen IM, van Mil SWC, Kersten S.
    J Hepatol; 2016 May; 64(5):1158-1166. PubMed ID: 26812075
    [Abstract] [Full Text] [Related]

  • 24. Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.
    Kristiansen MN, Veidal SS, Rigbolt KT, Tølbøl KS, Roth JD, Jelsing J, Vrang N, Feigh M.
    World J Hepatol; 2016 Jun 08; 8(16):673-84. PubMed ID: 27326314
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
    Pockros PJ, Fuchs M, Freilich B, Schiff E, Kohli A, Lawitz EJ, Hellstern PA, Owens-Grillo J, Van Biene C, Shringarpure R, MacConell L, Shapiro D, Cohen DE.
    Liver Int; 2019 Nov 08; 39(11):2082-2093. PubMed ID: 31402538
    [Abstract] [Full Text] [Related]

  • 27. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
    Briand F, Brousseau E, Quinsat M, Burcelin R, Sulpice T.
    Eur J Pharmacol; 2018 Jan 05; 818():449-456. PubMed ID: 29155143
    [Abstract] [Full Text] [Related]

  • 28. Beneficial effects of elafibranor on NASH in E3L.CETP mice and differences between mice and men.
    van den Hoek AM, Verschuren L, Caspers MPM, Worms N, Menke AL, Princen HMG.
    Sci Rep; 2021 Mar 03; 11(1):5050. PubMed ID: 33658534
    [Abstract] [Full Text] [Related]

  • 29. Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3.
    Fan YY, Ding W, Zhang C, Fu L, Xu DX, Chen X.
    Int Immunopharmacol; 2019 Dec 03; 77():105911. PubMed ID: 31671330
    [Abstract] [Full Text] [Related]

  • 30. Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH.
    Alkhouri N, LaCerte C, Edwards J, Poordad F, Lawitz E, Lee L, Karan S, Sawhney S, Erickson M, MacConell L, Zaru L, Chen J, Campagna J.
    Liver Int; 2024 Apr 03; 44(4):966-978. PubMed ID: 38293761
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
    Loomba R, Sanyal AJ, Kowdley KV, Terrault N, Chalasani NP, Abdelmalek MF, McCullough AJ, Shringarpure R, Ferguson B, Lee L, Chen J, Liberman A, Shapiro D, Neuschwander-Tetri BA.
    Gastroenterology; 2019 Jan 03; 156(1):88-95.e5. PubMed ID: 30222962
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis.
    Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M, Nevens F, van Grunsven LA, Trebicka J, Laleman W.
    Sci Rep; 2016 Sep 16; 6():33453. PubMed ID: 27634375
    [Abstract] [Full Text] [Related]

  • 38. SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.
    Zhou J, Cui S, He Q, Guo Y, Pan X, Zhang P, Huang N, Ge C, Wang G, Gonzalez FJ, Wang H, Hao H.
    Nat Commun; 2020 Jan 13; 11(1):240. PubMed ID: 31932588
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Effects of apical sodium-bile acid transporter inhibitor and obeticholic acid co-treatment in experimental non-alcoholic steatohepatitis.
    Matye DJ, Qin X, Hasan MN, Gu L, Clayton YD, Li F, Li T.
    Liver Res; 2022 Dec 13; 6(4):276-283. PubMed ID: 36819659
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.